Work

OA01.04 IMpower010 5-y Subgroup Analysis and Relapse Patterns: Phase 3 Study of Atezolizumab vs BSC in Stage II-IIIA NSCLC

Year: 2024

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2024.09.023

Authors: E. Felip, H.A. Wakelee, E. Vallieres, A. Martinez-Marti, O. Goloborodko, C. Zhou, A. Rittmeyer, A. Chella, M. Reck, T. Csoszi, I. Bondarenko, H. Kenmotsu, W. Schutte, B. Ding, Q. Zhu, M. Ballinger, E. Bennett, B.J. Gitlitz, N. Altorki

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Stanford Cancer Institute, Stanford University, Swedish Medical Center, Tongji University, Shanghai Pulmonary Hospital, Azienda Ospedaliera Universitaria Pisana, German Center for Lung Research, LungenClinic Grosshansdorf, Dnipro State Medical University, Shizuoka Cancer Center, Genentech, NewYork–Presbyterian Hospital, Weill Cornell Medicine

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4403420164

Cites:

Cited by: 6

Related to: 10